Categories Cancer Treatment
Relevance: Medium-High
Most relevant for: People with colorectal cancer or at risk of colorectal cancer
Update: News from the FDA: Colorectal cancer screening and treatment
This XRAY review is a summary of FDA colorectal cancer (CRC) updates in the last year, including education regarding CRC screening, three treatment drugs targeting different types of CRC and two colorectal screening tests. (Posted 4/16/25)
Este artículo está disponible en español
READ MORE ›
Relevance: Medium-High
Most relevant for: Premenopausal women before or during early breast cancer treatment
Update: Ovarian suppression may reduce breast cancer recurrence
Ovarian suppression—blocking estrogen production in the ovaries—can improve breast cancer outcomes in premenopausal women. This review provides information about ovarian suppression and describes who might benefit. (Posted 3/6/25)
Este artículo está disponible en español.
Relevance: Medium-High
Most relevant for: Young women with breast cancer concerned about survivorship issues
Topic: Addressing the needs of young adults with breast cancer
This update addresses common concerns faced by young adults with breast cancer, particularly fertility and childbearing, psychosocial health and treatment-related side effects. (Posted 2/28/25)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium
Most relevant for: People with an inherited mutation in CDKN2A
Article: Life with a high-risk pancreatic and melanoma cancer mutation
One woman seeks genetic testing after her sister died of pancreatic cancer. Despite how her family’s mutation in the CDKN2A gene resulted in multiple cancer diagnoses and deaths and a suspicious finding during her own pancreatic cancer screening, Amarensia Spruitenburg shares a message of hope and gratitude. By telling her story, Amarensia highlights the impact that hereditary cancer can have on families. (Posted 11/22/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-High
Most relevant for: People with endometrial cancer
Update: News from the FDA: New endometrial cancer approvals
The FDA recently approved three new immunotherapy treatments (Jemperli, Imfinzi and Keytruda) for advanced endometrial cancer. (Posted 11/7/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium
Most relevant for: People considering fertility preservation.
Study: Impact of breast cancer and BRCA mutations on fertility preservation
Timely family planning discussions are important for people diagnosed with breast cancer as well as those who have an inherited a BRCA1 or BRCA2 mutation. This study looked at the number of mature eggs recovered when ovaries were stimulated for fertility preservation or preimplantation genetic testing among three groups and found that the number of eggs collected was similar. (Posted 10/31/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-High
Most relevant for: People with advanced endometrial cancer
Study: Managing the side effects of advanced endometrial cancer treatment
Immunotherapy plus targeted therapy is a treatment option for advanced endometrial cancer that has progressed after prior treatment. People who start the two-drug combination are more likely to have a positive experience if they learn about the possible side effects and when they might occur. The most common side effects and how to manage them are discussed in this review. (Posted 9/25/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: High
Most relevant for: People with Her2-positive metastatic breast cancer
Study: Combining two anti-HER2 drugs improves outcomes more effectively than one
Combining two anti-HER2 drugs increased the time until cancer returned for people with locally advanced or metastatic HER2-positive breast cancer compared to people who received just one anti-HER2 drug. People whose breast cancer had metastasized to the brain also benefitted from the two combined drugs. (Posted 9/17/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium
Most relevant for: People with prostate cancer
Update: News from the FDA: First-line treatment and biosimilars for prostate cancer
The FDA recently approved a first-line treatment for non-metastatic, castration-sensitive prostate cancer. Approval was also given to two new drugs known as biosimilars that can be used in place of two already approved biologics to prevent bone weakening, pain or fractures that may occur from certain hormone therapies or from cancer that has spread to the bone. (Posted 9/10/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-High
Most relevant for: People with Lynch syndrome and people with colorectal cancer who may have Lynch syndrome
Study: Colorectal cancer in people with Lynch syndrome can include types of cancer found more typically in people without Lynch syndrome
When people with Lynch syndrome (LS) develop cancer, their tumors typically have a related set of features or biomarkers known as deficient mismatch repair (dMMR) and high microsatellite instability (MSI-High). However, occasionally people with Lynch syndrome have cancers that are proficient in mismatch repair (pMMR or MMR-P) and have microsatellite stability (MSS or MSI-Low) –more like the colorectal cancers found in people without Lynch syndrome. This study shows that 10 percent of people with Lynch syndrome may have these types of cancers. This can change treatment recommendations. (Posted 9/5/24)
Este artículo está disponible en español.
READ MORE ›